GlaxoSmithKline study shows competitor Effexor XR worsens sexual function of depressed patients

By Angela McDaniels

Seattle, Nov. 10 - GlaxoSmithKline said that sexual functioning worsened in patients with major depressive disorder treated in a study with Wyeth Pharmaceutical's Effexor XR as compared to patients treated with GlaxoSmithKline's Wellbutrin XL.

The company presented the study results Wednesday at the 18th Annual U.S. Psychiatric & Mental Health Congress in Las Vegas.

The 12-week, multi-center study compared Wellbutrin XL and Effexor XR in 342 adult outpatients with regard to sexual functioning, efficacy and safety.

Effexor XR negatively impacted multiple domains of sexual functioning including intensity of desire, frequency of desire and orgasm, the company said.

Sexual function was not impacted by Wellbutrin XL, the company said.

GlaxoSmithKline is a pharmaceutical company with U.S. operations in Philadelphia and Research Triangle Park, N.C.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.